HomeCompareMDT vs ALGN

MDT vs ALGN: Dividend Comparison 2026

MDT yields 3.31% · ALGN yields 1.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MDT wins by $32.9K in total portfolio value
10 years
MDT
MDT
● Live price
3.31%
Share price
$85.74
Annual div
$2.84
5Y div CAGR
29.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$54.3K
Annual income
$9,789.15
Full MDT calculator →
ALGN
ALGN
● Live price
1.20%
Share price
$166.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$130.06
Full ALGN calculator →

Portfolio growth — MDT vs ALGN

📍 MDT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMDTALGN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MDT + ALGN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MDT pays
ALGN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MDT
Annual income on $10K today (after 15% tax)
$281.55/yr
After 10yr DRIP, annual income (after tax)
$8,320.78/yr
ALGN
Annual income on $10K today (after 15% tax)
$102.25/yr
After 10yr DRIP, annual income (after tax)
$110.55/yr
At 15% tax rate, MDT beats the other by $8,210.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MDT + ALGN for your $10,000?

MDT: 50%ALGN: 50%
100% ALGN50/50100% MDT
Portfolio after 10yr
$37.8K
Annual income
$4,959.61/yr
Blended yield
13.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MDT right now

MDT
Analyst Ratings
1
Strong
26
Buy
22
Hold
Consensus: Buy
Price Target
$111.45
+30.0% upside vs current
Range: $100.00 — $120.00
Altman Z
2.9
Piotroski
7/9
ALGN
Analyst Ratings
24
Buy
7
Hold
2
Sell
Consensus: Buy
Price Target
$197.30
+18.7% upside vs current
Range: $140.00 — $220.00
Altman Z
4.9
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MDT buys
0
ALGN buys
0
No recent congressional trades found for MDT or ALGN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMDTALGN
Forward yield3.31%1.20%
Annual dividend / share$2.84$2.00
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR29.3%0%
Portfolio after 10y$54.3K$21.4K
Annual income after 10y$9,789.15$130.06
Total dividends collected$29.9K$1.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusBuyBuy
Analyst price target$111.45$197.30

Year-by-year: MDT vs ALGN ($10,000, DRIP)

YearMDT PortfolioMDT Income/yrALGN PortfolioALGN Income/yrGap
1← crossover$11,128$428.29$10,820$120.29+$308.00MDT
2$12,483$575.94$11,699$121.65+$784.00MDT
3$14,138$780.71$12,641$122.92+$1.5KMDT
4$16,196$1,068.46$13,650$124.13+$2.5KMDT
5$18,809$1,479.09$14,731$125.27+$4.1KMDT
6$22,201$2,075.70$15,889$126.34+$6.3KMDT
7$26,716$2,960.69$17,128$127.36+$9.6KMDT
8$32,891$4,305.30$18,455$128.31+$14.4KMDT
9$41,599$6,405.16$19,876$129.21+$21.7KMDT
10$54,300$9,789.15$21,398$130.06+$32.9KMDT

MDT vs ALGN: Complete Analysis 2026

MDTHealthcare

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Full MDT Calculator →

ALGNStock

Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.

Full ALGN Calculator →
📬

Get this MDT vs ALGN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MDT vs SCHDMDT vs JEPIMDT vs OMDT vs KOMDT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.